BioSpace News Archive

ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia following feedback from the U.S. Food and Drug Administration.

PDS Biotechnology Corporation (Nasdaq: PDSB), today announced that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) to provide up to a $35.0 million term loan.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to present at the Lake Street 6th Annual Best Ideas Growth Conference being held September 14, 2022.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

IRIS - Intelligent Retinal Imaging Systems, a leader in retinal screening technology, has partnered with HealPros, a technology-enabled healthcare service that works with some of the largest health plans in the nation to change the lives of people with chronic illness.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.

Glaucoma is one of the leading causes of vision loss and blindness, affecting over 3 million Americans, blinding over 120,000.

Arcus Biosciences announced that its management team will participate in the following upcoming investor conferences.

Penumbra, Inc. announced that its management team is scheduled to present at the following investor conferences.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors.